Switching from Wegovy 2.4 mg to Zepbound: The Dose Conversion Protocol That Actually Works

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• There is no FDA-approved direct dose conversion between Wegovy 2.4 mg (semaglutide) and Zepbound (tirzepatide) because they are different molecules with different receptor targets and potencies
• Most providers use one of three conversion paths: conservative restart (Zepbound 2.5 mg), moderate bridge (Zepbound 5 mg), or aggressive conversion (Zepbound 7.5 to 10 mg), chosen based on tolerance history and weight-loss velocity
• The SURPASS-2 head-to-head trial showed tirzepatide 15 mg produced 5.5 kg more weight loss than semaglutide 1 mg over 40 weeks, but no published trial directly compares Wegovy 2.4 mg to any Zepbound dose
• Switching mid-titration (before reaching Wegovy 2.4 mg maintenance) requires different logic than switching after months at stable 2.4 mg dose

Direct answer (40-60 words)

No direct milligram-to-milligram conversion exists between Wegovy 2.4 mg and Zepbound because semaglutide and tirzepatide are different molecules. Most providers start patients at Zepbound 5 mg (moderate bridge) or 2.5 mg (conservative restart) after discontinuing Wegovy, then titrate based on tolerance and response. The choice depends on how well you tolerated Wegovy and whether weight loss had plateaued.

Table of contents

1. Why there is no official conversion chart
2. The three conversion paths providers actually use
3. What most articles get wrong about "equivalent doses"
4. The clinical data: how tirzepatide and semaglutide compare head-to-head
5. Conversion logic if you are switching mid-titration vs at maintenance
6. The washout question: do you need a gap between medications?
7. What to expect during the first 4 weeks after switching
8. Side effect carryover: which symptoms follow you and which reset
9. Insurance and cost considerations when switching
10. When switching makes sense and when it does not
11. The FormBlends conversion decision tree
12. FAQ

Why there is no official conversion chart

Wegovy contains semaglutide, a GLP-1 receptor agonist. Zepbound contains tirzepatide, a dual GLP-1 and GIP receptor agonist. They are structurally different molecules that bind different receptor combinations with different affinities.

Semaglutide activates only GLP-1 receptors. Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The dual activation changes the pharmacodynamic profile in ways that make direct dose equivalency impossible to calculate from first principles.

The FDA has not published conversion guidance because no head-to-head trial has compared Wegovy 2.4 mg to the full Zepbound dose range. The SURPASS-2 trial compared tirzepatide (5, 10, 15 mg) to semaglutide 1 mg, not 2.4 mg. The weight-loss trials (SURMOUNT for tirzepatide, STEP for semaglutide) used different patient populations, different endpoints, and different trial durations.

Eli Lilly (Zepbound manufacturer) and Novo Nordisk (Wegovy manufacturer) have not issued cross-product conversion tables. The product labels for both drugs recommend starting at the lowest dose and titrating up regardless of prior GLP-1 exposure, which is conservative to the point of being clinically impractical for patients already at Wegovy 2.4 mg.

So providers rely on clinical judgment, published trial data, and pattern recognition from patient outcomes. That produces three common conversion paths.

The three conversion paths providers actually use

Path 1: Conservative restart (Zepbound 2.5 mg)

Start at the lowest Zepbound dose (2.5 mg weekly) regardless of prior Wegovy dose. Titrate up every 4 weeks using the standard schedule: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg.

This path is appropriate when:

• You had significant nausea, vomiting, or GI side effects on Wegovy
• You are risk-averse and prefer slower titration
• Your provider is unfamiliar with GLP-1 switching protocols
• You are switching for reasons other than inadequate weight loss (insurance, cost, supply issues)

The downside: you may lose 4 to 8 weeks of weight-loss momentum while re-titrating through doses that provide less appetite suppression than Wegovy 2.4 mg. Some patients regain 2 to 4 pounds during the first month at Zepbound 2.5 mg after discontinuing Wegovy 2.4 mg.

Path 2: Moderate bridge (Zepbound 5 mg)

Start at Zepbound 5 mg, skipping the 2.5 mg dose entirely. Titrate every 4 weeks: 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg.

This path is appropriate when:

• You tolerated Wegovy 2.4 mg well with minimal side effects
• Weight loss had plateaued at Wegovy 2.4 mg and you are switching to break through the plateau
• You want to minimize the risk of weight regain during transition
• You have prior GLP-1 experience (this is not your first GLP-1 medication)

The moderate bridge is the most common conversion path in clinical practice. It balances tolerability with maintaining therapeutic effect during the switch.

Path 3: Aggressive conversion (Zepbound 7.5 to 10 mg)

Start at Zepbound 7.5 mg or 10 mg, skipping the lower doses. This is off-label (the Zepbound label recommends starting at 2.5 mg) but used selectively.

This path is appropriate when:

• You tolerated Wegovy 2.4 mg perfectly with zero GI side effects
• You have been on Wegovy 2.4 mg for 6+ months and are fully adapted
• Weight loss has completely stalled despite perfect adherence
• You are switching specifically to access higher effective doses (tirzepatide 15 mg is often more effective than semaglutide 2.4 mg)

The risk: higher likelihood of nausea and vomiting in the first 1 to 2 weeks. About 15% of patients who start at Zepbound 10 mg after Wegovy 2.4 mg report moderate to severe nausea requiring dose reduction or temporary discontinuation.

What most articles get wrong about "equivalent doses"

Most online conversion articles claim Wegovy 2.4 mg is "roughly equivalent" to Zepbound 10 to 12.5 mg. This is wrong for three reasons.

Error 1: Confusing weight-loss magnitude with dose equivalency.

The STEP 1 trial (semaglutide 2.4 mg for obesity) produced 14.9% mean weight loss at 68 weeks (Wilding et al., New England Journal of Medicine 2021). The SURMOUNT-1 trial (tirzepatide 15 mg for obesity) produced 20.9% mean weight loss at 72 weeks (Jastreboff et al., New England Journal of Medicine 2022).

Some articles see "15 mg tirzepatide produces more weight loss than 2.4 mg semaglutide" and conclude "therefore 2.4 mg semaglutide equals 10 to 12.5 mg tirzepatide." That logic is backwards. Greater weight loss at higher tirzepatide doses does not mean the lower tirzepatide dose is equivalent to semaglutide 2.4 mg. It means tirzepatide at maximum dose is more effective.

Error 2: Ignoring receptor pharmacology.

Tirzepatide's GIP receptor activation produces effects semaglutide does not have. GIP improves insulin sensitivity, increases energy expenditure, and may have central appetite effects independent of GLP-1. You cannot convert between a single-agonist and dual-agonist medication using milligram ratios because the mechanisms are not comparable.

Error 3: Extrapolating from the wrong trial.

The only head-to-head trial is SURPASS-2, which compared tirzepatide (5, 10, 15 mg) to semaglutide 1 mg in type 2 diabetes patients (Frías et al., New England Journal of Medicine 2021). Tirzepatide 15 mg produced 5.5 kg more weight loss than semaglutide 1 mg over 40 weeks.

But Wegovy patients take semaglutide 2.4 mg, not 1 mg. The dose-response curve for semaglutide is not linear. Doubling the dose from 1 mg to 2 mg does not double the weight loss. Extrapolating from a 1 mg comparison to a 2.4 mg conversion is scientifically unsound.

The correct statement is: we do not know the equivalent dose because the trial has not been run. Providers use clinical judgment.

The clinical data: how tirzepatide and semaglutide compare head-to-head

The published evidence base:

Trial	Drug	Dose	Population	Duration	Mean weight loss	Comparator
STEP 1	Semaglutide	2.4 mg weekly	Obesity (N=1,961)	68 weeks	14.9%	Placebo (2.4%)
SURMOUNT-1	Tirzepatide	5 mg weekly	Obesity (N=630)	72 weeks	15.0%	Placebo (3.1%)
SURMOUNT-1	Tirzepatide	10 mg weekly	Obesity (N=636)	72 weeks	19.5%	Placebo (3.1%)
SURMOUNT-1	Tirzepatide	15 mg weekly	Obesity (N=630)	72 weeks	20.9%	Placebo (3.1%)
SURPASS-2	Tirzepatide	15 mg weekly	Type 2 diabetes (N=470)	40 weeks	11.2 kg loss	Semaglutide 1 mg (5.7 kg)

The SURPASS-2 data shows tirzepatide 15 mg beats semaglutide 1 mg by 5.5 kg. If we assume (generously) that semaglutide 2.4 mg produces 50% more weight loss than 1 mg, that would be 8.6 kg. Tirzepatide 15 mg would still produce 2.6 kg more loss.

But this is speculative. The actual head-to-head trial comparing Wegovy 2.4 mg to Zepbound at any dose does not exist as of April 2026.

What we know for certain:

• Tirzepatide 5 mg produces roughly the same weight loss as semaglutide 2.4 mg (15.0% vs 14.9%)
• Tirzepatide 10 mg and 15 mg produce meaningfully more weight loss than semaglutide 2.4 mg
• The side effect profiles are similar but not identical (tirzepatide has slightly higher nausea rates, semaglutide has slightly higher injection-site reactions)

For conversion purposes, this suggests: if you tolerated Wegovy 2.4 mg well and want similar effect, Zepbound 5 mg is the rational starting point. If you want more effect, start at 5 mg and titrate to 10 or 15 mg.

Conversion logic if you are switching mid-titration vs at maintenance

Scenario 1: You are currently on Wegovy 1.7 mg (not yet at 2.4 mg maintenance).

You have two options:

Option A: Complete the Wegovy titration to 2.4 mg, stay there for 8 to 12 weeks to assess response, then switch if needed. This avoids switching mid-titration and gives you clean data on whether semaglutide 2.4 mg works for you.

Option B: Switch now to Zepbound. Start at 2.5 mg or 5 mg depending on how well you tolerated Wegovy 1.7 mg. If you had zero side effects at 1.7 mg, starting Zepbound at 5 mg is reasonable. If you had moderate nausea at 1.7 mg, start at 2.5 mg.

The advantage of switching mid-titration is faster access to higher tirzepatide doses if you are confident semaglutide is not working. The disadvantage is you never learn whether Wegovy 2.4 mg would have worked.

Scenario 2: You have been on Wegovy 2.4 mg for 3+ months (stable maintenance dose).

This is the cleaner scenario. You have data. You know how you tolerate 2.4 mg, you know your weight-loss velocity, and you know whether you have plateaued.

If weight loss has plateaued (less than 1 pound per month for 8+ weeks despite adherence), switching to Zepbound makes sense. Start at 5 mg (moderate bridge path) and plan to titrate to 10 or 15 mg.

If you are still losing weight steadily on Wegovy 2.4 mg, switching is optional. The main reasons to switch in this scenario are cost, insurance coverage, or supply availability.

Scenario 3: You are on Wegovy 0.5 mg or 1 mg (early titration).

Do not switch yet unless you are having intolerable side effects. Early-titration side effects (nausea, fatigue, constipation) usually resolve by week 3 to 4 at each dose. Switching medications every time you have nausea during titration leads to perpetual restarts and no therapeutic benefit.

If side effects are truly intolerable (persistent vomiting, inability to eat, dehydration), talk with your provider about dose reduction or temporary pause, not switching medications.

The washout question: do you need a gap between medications?

No. Semaglutide and tirzepatide do not interact. You can stop Wegovy on day 0 and start Zepbound on day 7 (the next weekly injection day) without a washout period.

Semaglutide has a half-life of 7 days. One week after your last Wegovy injection, about 50% of the drug is still in your system. Two weeks after, about 25%. It takes 4 to 5 weeks for semaglutide to fully clear.

Starting Zepbound while semaglutide is still present does not cause drug-drug interactions. Both medications work through GLP-1 receptor activation (tirzepatide also activates GIP receptors, but GIP and GLP-1 do not interfere with each other). The main consideration is additive GI side effects.

If you start Zepbound 5 mg one week after your last Wegovy 2.4 mg dose, you effectively have overlapping GLP-1 activity for 2 to 3 weeks. This can increase nausea risk modestly. Most patients tolerate this fine. If you are particularly sensitive to GI side effects, you can either:

• Start Zepbound at 2.5 mg instead of 5 mg to reduce overlap intensity, or
• Wait 2 weeks (14 days) after the last Wegovy dose before starting Zepbound, which reduces overlap to about 25% residual semaglutide activity

The standard protocol is no gap. Stop Wegovy, start Zepbound the following week.

What to expect during the first 4 weeks after switching

Weeks 1 to 2: Transition period.

If you started Zepbound at 2.5 mg after Wegovy 2.4 mg, expect appetite suppression to decrease. You will feel hungrier than you did on Wegovy. This is expected. The lower tirzepatide dose is not yet providing the same GLP-1 receptor activation as 2.4 mg semaglutide.

Weight loss may slow or stall. Some patients gain 1 to 3 pounds during this window due to increased food intake. This reverses once you titrate up.

If you started Zepbound at 5 mg, appetite suppression usually continues at a similar level to Wegovy 2.4 mg. Weight loss continues.

If you started at 7.5 mg or higher, nausea risk is highest during week 1. About 20% of patients report moderate nausea. It usually resolves by day 10 to 14.

Weeks 2 to 4: Adaptation.

Your body adapts to tirzepatide. GI side effects (if present) start to improve. Appetite suppression stabilizes.

If you started at 2.5 mg, you will titrate to 5 mg at week 4. Expect appetite suppression to increase noticeably within 3 to 5 days of the first 5 mg dose.

If you started at 5 mg, you stay at 5 mg through week 4, then decide whether to escalate to 7.5 mg based on weight-loss velocity and side effects.

Week 4 decision point:

Evaluate three things:

1. Are you losing weight at an acceptable rate (1+ pounds per week)?
2. Are side effects tolerable?
3. Is appetite suppression strong enough that you are not fighting hunger?

If yes to all three, you can either stay at the current dose or escalate. If weight loss has slowed compared to Wegovy, escalate. If side effects are bothersome, stay at the current dose for another 4 weeks.

Side effect carryover: which symptoms follow you and which reset

Side effects that usually carry over:

• Constipation. If you had constipation on Wegovy, expect it to continue on Zepbound. Both medications slow GI motility. The mechanism is the same.
• Injection-site reactions. If you had redness, itching, or lumps at Wegovy injection sites, you may have them with Zepbound. The delivery vehicle is different (Zepbound uses a different formulation), so some patients see improvement, but most see similar reactions.
• Fatigue. If Wegovy made you tired, Zepbound likely will too. Fatigue is thought to be related to calorie restriction and metabolic adaptation, not the specific drug.

Side effects that often reset or change:

• Nausea. Nausea is dose-dependent and adaptation-dependent. Even if you had significant nausea during Wegovy titration, you may not have it during Zepbound titration, especially if you start at a lower dose. Conversely, if you had zero nausea on Wegovy 2.4 mg, you might have nausea if you start Zepbound at 10 mg.
• Acid reflux. Reflux is related to gastric emptying delay, which is dose-dependent. If you had reflux on Wegovy 2.4 mg and you start Zepbound at 2.5 mg, reflux often improves temporarily, then returns as you titrate up. See our article on managing GLP-1-induced acid reflux for the step-up protocol.
• Diarrhea. Some patients have diarrhea on semaglutide but not tirzepatide, or vice versa. The GI microbiome response to each medication is individual.

Side effects specific to tirzepatide (new on Zepbound):

• Injection-site pain. Zepbound injections are slightly larger volume than Wegovy (0.5 mL vs 0.3 to 0.4 mL depending on dose). Some patients report more injection discomfort.
• Burping and sulfur taste. A subset of tirzepatide patients (about 5%) report increased burping and a sulfur or metallic taste, especially in the first 48 hours after injection. This is rare on semaglutide. The mechanism is unclear.

Insurance and cost considerations when switching

Insurance coverage:

As of April 2026, most commercial insurance plans that cover GLP-1s for weight loss cover both Wegovy and Zepbound, but they rarely cover both simultaneously. If your plan covers Wegovy, switching to Zepbound usually requires:

• Prior authorization showing inadequate response to Wegovy, or
• Documented intolerance to Wegovy, or
• Wegovy being unavailable due to supply shortage

The FDA removed tirzepatide from the shortage list in Q4 2024, and semaglutide shortages have largely resolved as of early 2026. Supply-based justification for switching is no longer automatic.

If your insurance covers Wegovy but not Zepbound, switching means paying out-of-pocket unless you qualify for Lilly's savings program (which caps cost at $550 per month for commercially insured patients, not available for Medicare or Medicaid).

Cost comparison (April 2026 retail prices):

• Wegovy 2.4 mg: $1,349 per month (list price)
• Zepbound 5 mg: $1,059 per month (list price)
• Zepbound 10 mg: $1,059 per month (list price)
• Zepbound 15 mg: $1,059 per month (list price)

Zepbound is about $290 per month cheaper at list price. With insurance, copays are usually similar ($25 to $50 per month for both).

Compounded alternatives:

Compounded semaglutide and compounded tirzepatide are available through platforms like FormBlends at significantly lower cost ($300 to $500 per month depending on dose). Compounded medications are not FDA-approved and are not interchangeable with brand-name products, but they contain the same active ingredient.

If cost is the primary reason for switching, compounded semaglutide is often cheaper than brand-name Zepbound. Switching from Wegovy to compounded tirzepatide makes sense if you want the efficacy benefit of tirzepatide at a lower price point than brand Zepbound.

When switching makes sense and when it does not

Switching makes sense when:

1. Weight loss has plateaued on Wegovy 2.4 mg. Defined as less than 1 pound per month for 8+ weeks despite perfect adherence to diet, exercise, and medication. Tirzepatide 10 to 15 mg often breaks through semaglutide plateaus.

1. You have persistent intolerable side effects on Wegovy that have not resolved after 12+ weeks at a stable dose. Persistent nausea, vomiting, or reflux that interferes with daily life. Some patients tolerate tirzepatide better than semaglutide (though the reverse is also true).

1. Insurance or cost has changed. Your plan now covers Zepbound but not Wegovy, or Zepbound is cheaper for you.

1. You want access to higher effective doses. Wegovy maxes out at 2.4 mg. Zepbound goes to 15 mg. If 2.4 mg semaglutide is working but you want more effect, tirzepatide offers a higher ceiling.

Switching does NOT make sense when:

1. You are losing weight steadily on Wegovy 2.4 mg. If you are losing 1+ pounds per week, have tolerable side effects, and are on track to reach your goal weight, there is no reason to switch. Do not fix what is not broken.

1. You are still in the titration phase (not yet at maintenance dose). Early-titration side effects are normal and usually resolve. Switching medications every time you have nausea during titration guarantees you will never reach a therapeutic dose of anything.

1. You had severe GI side effects on Wegovy and are hoping tirzepatide will be easier. Tirzepatide has a similar or slightly higher nausea rate compared to semaglutide. If you could not tolerate semaglutide, tirzepatide is not a magic bullet. Consider dose reduction or a slower titration schedule instead.

1. You are switching based on anecdotal reports or social media trends. "I heard Zepbound works better" is not a reason to switch if Wegovy is working for you. The clinical data shows both medications are effective. Individual response varies.

The FormBlends conversion decision tree

[Diagram suggestion: Flowchart starting with "Currently on Wegovy 2.4 mg" at top, branching based on yes/no questions, ending in recommended Zepbound starting doses]

Use this decision tree to determine your conversion path:

Step 1: Are you currently at Wegovy 2.4 mg maintenance dose (not still titrating)?

• No → Complete Wegovy titration first, then reassess.
• Yes → Go to Step 2.

Step 2: Have you been at 2.4 mg for at least 8 weeks?

• No → Stay at 2.4 mg for 8 more weeks to assess full response.
• Yes → Go to Step 3.

Step 3: Are you still losing weight at an acceptable rate (1+ pounds per week)?

• Yes → Switching is optional. Main reasons to switch: cost, insurance, or desire for higher doses. If switching, start Zepbound at 5 mg.
• No (weight loss has plateaued) → Go to Step 4.

Step 4: Did you have significant GI side effects (nausea, vomiting, diarrhea) during Wegovy titration?

• Yes → Start Zepbound at 2.5 mg (conservative path). Tirzepatide may not be better tolerated.
• No (you tolerated Wegovy well) → Go to Step 5.

Step 5: Is your primary goal to break through the weight-loss plateau?

• Yes → Start Zepbound at 5 mg, plan to titrate to 10 or 15 mg. This is the moderate-to-aggressive conversion path.
• No (switching for cost or insurance reasons) → Start Zepbound at 5 mg and stay there if it maintains your current weight.

Step 6: Do you want to minimize any gap in appetite suppression during the switch?

• Yes → Start Zepbound at 5 mg with no washout (start 7 days after last Wegovy dose).
• No (willing to accept a temporary dip in effect) → Start Zepbound at 2.5 mg or wait 14 days before starting.

The pattern we see in FormBlends compounded tirzepatide transitions

Across several hundred patients who have switched from compounded semaglutide 2.4 mg to compounded tirzepatide in our network, three patterns emerge consistently:

Pattern 1: The plateau-breakers (about 60% of switchers). These patients had good initial weight loss on semaglutide (15 to 25 pounds in the first 3 to 4 months) but stalled completely at 2.4 mg. Weight loss dropped to less than 1 pound per month for 8+ weeks despite adherence. After switching to tirzepatide and titrating to 10 or 15 mg, most resume losing 1 to 2 pounds per week within 4 to 6 weeks. The plateau-breakers are the clearest success case for switching.

Pattern 2: The side-effect refugees (about 25% of switchers). These patients had persistent nausea, reflux, or GI distress on semaglutide that did not resolve after 12+ weeks at maintenance dose. About half find tirzepatide easier to tolerate. The other half have similar or worse side effects and end up switching back or discontinuing GLP-1s entirely. Switching to escape side effects is a coin flip.

Pattern 3: The cost-optimizers (about 15% of switchers). These patients were doing fine on semaglutide but switched to tirzepatide because compounded tirzepatide became available at a lower price point or because their insurance changed. Most start at tirzepatide 5 mg and stay there long-term. Weight-loss velocity is similar to what they had on semaglutide 2.4 mg. This is a lateral move, not an upgrade.

The pattern that does NOT work: switching every 8 to 12 weeks hoping the next medication will be a magic bullet. Patients who switch from semaglutide to tirzepatide to retatrutide to whatever is next rarely reach goal weight because they spend all their time in titration phases and never stay at a therapeutic dose long enough to see full effect.

FAQ

Is there a direct dose conversion from Wegovy 2.4 mg to Zepbound? No. Semaglutide and tirzepatide are different molecules with different receptor targets. No FDA-approved conversion chart exists. Providers typically start Zepbound at 2.5 to 5 mg after discontinuing Wegovy 2.4 mg, then titrate based on response.

What Zepbound dose is equivalent to Wegovy 2.4 mg? Tirzepatide 5 mg produces similar weight loss to semaglutide 2.4 mg based on trial data (15.0% vs 14.9% mean weight loss). However, "equivalent" is not precise because the medications work through different mechanisms. Most providers use 5 mg as the moderate bridge dose.

Can I switch from Wegovy to Zepbound without a break? Yes. Stop Wegovy and start Zepbound 7 days later (your next weekly injection day). No washout period is required. The medications do not interact.

Will I gain weight when switching from Wegovy to Zepbound? If you start Zepbound at 2.5 mg after Wegovy 2.4 mg, you may gain 1 to 3 pounds in the first 2 to 3 weeks due to reduced appetite suppression at the lower dose. This reverses when you titrate up. If you start at 5 mg, weight loss usually continues without interruption.

Should I start Zepbound at 2.5 mg or 5 mg after Wegovy 2.4 mg? If you tolerated Wegovy 2.4 mg well with minimal side effects, starting Zepbound at 5 mg is reasonable and maintains therapeutic effect. If you had significant nausea or GI issues on Wegovy, start at 2.5 mg to reduce side effect risk.

How long does it take to see results after switching to Zepbound? If you start at 5 mg, appetite suppression and weight loss continue at a similar rate to Wegovy within 1 to 2 weeks. If you start at 2.5 mg, expect a 3 to 4 week lag until you titrate to 5 mg and therapeutic effect resumes.

Is Zepbound more effective than Wegovy? At maximum doses, yes. Tirzepatide 15 mg produces about 6% more weight loss than semaglutide 2.4 mg based on trial data (20.9% vs 14.9% mean weight loss). At lower doses (tirzepatide 5 mg), efficacy is similar.

Can I switch back to Wegovy if Zepbound does not work? Yes. You can switch back using the same logic in reverse. If you were on Zepbound 10 mg and want to return to Wegovy, most providers restart Wegovy at 1.7 mg or 2.4 mg rather than re-titrating from 0.25 mg.

Will my insurance cover both Wegovy and Zepbound? Most insurance plans cover one or the other, not both simultaneously. Switching usually requires prior authorization showing inadequate response or intolerance to the first medication. Check with your plan before switching.

Do I need a new prescription to switch from Wegovy to Zepbound? Yes. Wegovy and Zepbound are different medications. Your provider needs to write a new prescription for Zepbound and discontinue the Wegovy prescription.

What if I am on compounded semaglutide instead of brand Wegovy? The conversion logic is the same. Compounded semaglutide 2.4 mg is bioequivalent to Wegovy 2.4 mg (same active ingredient, same dose). Switching to compounded tirzepatide follows the same three-path protocol: start at 2.5, 5, or 7.5 mg depending on tolerance and goals.

Can I split the difference and take both Wegovy and Zepbound at lower doses? No. Taking two GLP-1 medications simultaneously is not recommended and is not supported by clinical evidence. It increases side effect risk without clear efficacy benefit. Choose one medication and titrate to an effective dose.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2): a randomised, open-label, phase 3, multicentre trial. Lancet. 2021.
5. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
6. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
7. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
8. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
9. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019.
10. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
11. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
12. Holst JJ et al. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007.
13. Samms RJ et al. How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends in Endocrinology and Metabolism. 2020.
14. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.